Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 27;16(4):752-768.
doi: 10.3390/hematolrep16040072.

The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review

Affiliations
Review

The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review

Francesco Dondi et al. Hematol Rep. .

Abstract

Background: In the last years, different evidence has underlined a possible role for [11C]-methionine ([11C]MET) positron emission tomography (PET) imaging for the evaluation of lymphomas. The aim of this paper was, therefore, to review the available scientific literature focusing on this topic. Methods: A wide literature search of the PubMed/MEDLINE, Scopus and Cochrane Library databases was conducted in order to find relevant published articles investigating the role of [11C]MET in the assessment of lymphomas. Results: Eighteen studies were included in the systematic review and the main fields of application of this imaging modality were the evaluation of disease, therapy response assessment, prognostic evaluation and differential diagnosis with other pathological conditions. Conclusion: Even with heterogeneous evidence, a possible role for [11C]MET PET imaging in the assessment of lymphomas affecting both the whole body and the central nervous system was underlined. When compared to [18F]fluorodesoxyglucose ([18F]FDG) imaging, in general, similar results have been reported between the two modalities in these settings.

Keywords: 11C-methionine; DLBCL; PET; PET/CT; central nervous system; lymphoma; positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of the research of eligible studies evaluating the role of [11C]MET PET imaging in the assessment of lymphomas.
Figure 2
Figure 2
QUADAS-2 quality assessment for risk of bias and applicability concerns for the studies considered in the review.

Similar articles

Cited by

References

    1. Wang R., Xu B., Liu C., Guan Z., Zhang J., Li F., Sun L., Zhu H. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma. Br. J. Radiol. 2018;91:20180240. doi: 10.1259/bjr.20180240. - DOI - PMC - PubMed
    1. Buck A.K., Bommer M., Juweid M.E., Glatting G., Stilgenbauer S., Mottaghy F.M., Schulz M., Kull T., Bunjes D., Möller P., et al. First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine. J. Nucl. Med. 2008;49:1756–1762. doi: 10.2967/jnumed.108.055335. - DOI - PubMed
    1. Mugnaini E.N., Ghosh N. Lymphoma. Prim. Care. 2016;43:661–675. doi: 10.1016/j.pop.2016.07.012. - DOI - PubMed
    1. Jaffe E.S. Diagnosis and classification of lymphoma: Impact of technical advances. Semin. Hematol. 2019;56:30–36. doi: 10.1053/j.seminhematol.2018.05.007. - DOI - PMC - PubMed
    1. Dondi F., Pasinetti N., Gatta R., Albano D., Giubbini R., Bertagna F. Comparison between Two Different Scanners for the Evaluation of the Role of 18F-FDG PET/CT Semiquantitative Parameters and Radiomics Features in the Prediction of Final Diagnosis of Thyroid Incidentalomas. J. Clin. Med. 2022;11:615. doi: 10.3390/jcm11030615. - DOI - PMC - PubMed

LinkOut - more resources